medigraphic.com
ISSN 2007-6509 (Print)
Órgano oficial de la Asociación Mexicana de Medicina Transfusional A.C.

2013, Number 1

<< Back

Rev Mex Med Transfus 2013; 6 (1)

Efficacy and cost effectiveness of nucleic acid amplification testing (NAT) and serologic screening in preventing HBV, HCV and HIV transmission risk

Lelie N, Bruhn R, Custer B, Busch M, Kleinman S

Language: English
References: 5
Page: 37-39
PDF size: 135.04 Kb.


Text Extraction

Previous cost effectiveness analyses of NAT systems only gave credit to detection of window period (WP) NAT yield donations [and occult HBV infections (OBIs) in settings without anti-HBc testing] while not considering the vast majority of concordant NAT and serology positive infections.


REFERENCES

  1. Jackson BR, Busch MP, Stramer SL et al. The cost effectiveness of NAT for HIV, HCV and HBV in whole blood donations. Transfusion. 2003; 43:721-729.

  2. Kleinman SH, Lelie PN, Busch MP. Infectivity of human immunodeficiencyvirus-1, hepatitis V virus and hepatitis B virus and risk of transmission by transfusion. Transfusion. 2009:49:2454-89.

  3. Bruhn R, Lelie N, Custer B, Busch M, Kleinman S and the International NAT Study Group. Prevalence of HIV-RNA and antibody in first, lapsed and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion in press.

  4. Weusten J, Vemeulen M, Van Drimmelen H, Lelie PN. Refinement of a viral transmission risk model for blood donations in serconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion. 2011;51:203-15.

  5. Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, Funk MB, Nubling CM. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets. Transfusion. 2012;52: 431-9.




2020     |     www.medigraphic.com